JP2022526429A5 - - Google Patents

Info

Publication number
JP2022526429A5
JP2022526429A5 JP2021559892A JP2021559892A JP2022526429A5 JP 2022526429 A5 JP2022526429 A5 JP 2022526429A5 JP 2021559892 A JP2021559892 A JP 2021559892A JP 2021559892 A JP2021559892 A JP 2021559892A JP 2022526429 A5 JP2022526429 A5 JP 2022526429A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
htra1
protein
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526429A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027802 external-priority patent/WO2020210724A1/en
Publication of JP2022526429A publication Critical patent/JP2022526429A/ja
Publication of JP2022526429A5 publication Critical patent/JP2022526429A5/ja
Priority to JP2025093119A priority Critical patent/JP2025175283A/ja
Pending legal-status Critical Current

Links

JP2021559892A 2019-04-10 2020-04-10 Amdの処置のためのhtra1調節 Pending JP2022526429A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025093119A JP2025175283A (ja) 2019-04-10 2025-06-04 Amdの処置のためのhtra1調節

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962832182P 2019-04-10 2019-04-10
US62/832,182 2019-04-10
PCT/US2020/027802 WO2020210724A1 (en) 2019-04-10 2020-04-10 Htra1 modulation for treatment of amd

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025093119A Division JP2025175283A (ja) 2019-04-10 2025-06-04 Amdの処置のためのhtra1調節

Publications (2)

Publication Number Publication Date
JP2022526429A JP2022526429A (ja) 2022-05-24
JP2022526429A5 true JP2022526429A5 (cg-RX-API-DMAC7.html) 2023-04-17

Family

ID=72750902

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559892A Pending JP2022526429A (ja) 2019-04-10 2020-04-10 Amdの処置のためのhtra1調節
JP2025093119A Pending JP2025175283A (ja) 2019-04-10 2025-06-04 Amdの処置のためのhtra1調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025093119A Pending JP2025175283A (ja) 2019-04-10 2025-06-04 Amdの処置のためのhtra1調節

Country Status (6)

Country Link
US (1) US20230165976A1 (cg-RX-API-DMAC7.html)
EP (1) EP3953485A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022526429A (cg-RX-API-DMAC7.html)
CN (1) CN113966401A (cg-RX-API-DMAC7.html)
CA (1) CA3136119A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020210724A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113512564A (zh) * 2021-08-05 2021-10-19 呈诺再生医学科技(珠海横琴新区)有限公司 以iPSC来源的细胞为载体、基因治疗湿性年龄相关性黄斑变性
WO2023023278A2 (en) * 2021-08-18 2023-02-23 University Of Utah Research Foundation Multigene constructs for treatment of age-related macular degeneration and other complement dysregulation-related conditions
US20250003989A1 (en) * 2021-11-15 2025-01-02 The Children`S Medical Center Corporation Methods for tauopathy diagnosis and treatment

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2109945T3 (es) 1990-06-01 1998-02-01 Chiron Corp Composiciones y procedimientos para identificar moleculas biologicamente activas.
EP0604552B1 (en) 1991-09-18 1997-02-12 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
HUT72495A (en) 1992-10-01 1996-05-28 Cold Spring Harbor Lab Complex combinatorial chemical libraries encoded with tags
JPH09508353A (ja) 1993-11-02 1997-08-26 アフィマックス テクノロジーズ ナムローゼ フェンノートシャップ 分子多様性の合成及びスクリーニング
JPH10500112A (ja) 1994-05-06 1998-01-06 ファーマコピーア,インコーポレイテッド 組合せ ジヒドロベンゾピラン ライブラリー
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
DE19710159A1 (de) 1997-03-12 1998-10-01 Hoechst Ag In vitro Transkriptionsverfahren zum Screening von Naturstoffen und anderen chemischen Substanzen
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
AU2001250774B2 (en) 2000-02-08 2005-01-27 Sangamo Biosciences, Inc. Cells expressing zinc finger proteins for drug discovery
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
ATE418346T1 (de) 2004-04-08 2009-01-15 Sangamo Biosciences Inc Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
US7253273B2 (en) 2004-04-08 2007-08-07 Sangamo Biosciences, Inc. Treatment of neuropathic pain with zinc finger proteins
DK2447275T3 (en) 2006-07-13 2015-06-29 Univ Iowa Res Found Methods and reagents for the treatment of age-related macular degeneration
MX2009000909A (es) * 2006-07-26 2009-02-04 Univ Yale Diagnostico y tratamiento de degeneracion macular relacionada con la edad.
US7972787B2 (en) 2007-02-16 2011-07-05 Massachusetts Eye And Ear Infirmary Methods for detecting age-related macular degeneration
TW200911290A (en) * 2007-07-02 2009-03-16 Alcon Res Ltd RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration
EP2108705A1 (en) * 2008-04-08 2009-10-14 Universität Duisburg-Essen Method for analysing the epigenetic status of the HtrA 1 gene in a biological sample
BR112013023724A2 (pt) * 2011-03-15 2019-09-24 Univ Utah Res Found métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento
PE20141562A1 (es) 2011-10-14 2014-11-12 Genentech Inc Anticuerpos anti-htra1 y metodos de uso
EP2895624B1 (en) 2012-09-14 2022-06-01 University Of Utah Research Foundation Methods of predicting the development of amd based on chromosome 1 and chromosome 10
CN111218447B (zh) * 2013-11-07 2024-10-11 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
MX388127B (es) * 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
SG11201608701QA (en) 2014-04-18 2016-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
EP3551757A1 (en) 2016-12-08 2019-10-16 Intellia Therapeutics, Inc. Modified guide rnas
US11674138B2 (en) * 2017-03-13 2023-06-13 President And Fellows Of Harvard College Methods of modulating expression of target nucleic acid sequences in a cell
WO2020019002A1 (en) 2018-07-20 2020-01-23 University Of Utah Research Foundation Gene therapy for macular degeneration
US20200291427A1 (en) * 2018-11-16 2020-09-17 Gemini Therapeutics Inc. Crispr-based therapeutics for targeting htra1 and methods of use
EP4667578A3 (en) * 2019-04-03 2026-04-01 REGENXBIO Inc. Gene therapy for eye pathologies

Similar Documents

Publication Publication Date Title
JP2022549380A5 (cg-RX-API-DMAC7.html)
WO2023284879A1 (en) Modified aav capsid for gene therapy and methods thereof
US20180258424A1 (en) Crispr compositions and methods of using the same for gene therapy
JP2022508182A5 (cg-RX-API-DMAC7.html)
US20260022154A1 (en) Gene therapies for stargardt disease (abca4)
EP3298134B1 (en) Gene editing of deep intronic mutations
JP2022535749A5 (cg-RX-API-DMAC7.html)
CA2979120A1 (en) Multiple aav vector system for expressing genes over 5 kilobases, comprising at least one degradation signal and uses thereof
WO2016100575A1 (en) Gene therapy for juvenile batten disease
CN113557243A (zh) 用于神经变性疾病的基因疗法
JP2017529395A5 (cg-RX-API-DMAC7.html)
US12173304B2 (en) Intron fragments
RU2018145010A (ru) Оптимизированные гены и экспрессионные кассеты cln1, и их применение
JP2023537980A5 (cg-RX-API-DMAC7.html)
US20250066433A1 (en) Modulators of Chromosome 9 Open Reading Frame 72 Gene Expression and Uses Thereof
JP2021520811A5 (cg-RX-API-DMAC7.html)
JP2022530095A5 (cg-RX-API-DMAC7.html)
JP2023500793A5 (cg-RX-API-DMAC7.html)
US12270033B2 (en) Dual leucine zipper kinase inhibitors for gene therapy
CN112424368A (zh) 用于调节眼内压和颅内压的材料和方法
AU2022282057B2 (en) Novel dual helper plasmid
JP2023541444A5 (cg-RX-API-DMAC7.html)
JP2024537167A5 (cg-RX-API-DMAC7.html)
US12480098B1 (en) Adeno-associated virus variant
KR102874560B1 (ko) 아데노연관바이러스 변이체